relief medicine Buscopan (hyoscine butylbromide), among others. Sales in the business totalled €5.6bn ($5.8bn) in 2023, accounting for 11% of Sanofi’s total business. Sanofi also claims Opella ...

In its third-quarter results update, Sanofi said the consumer health unit – which owns brands like allergy therapies Allegra and Xyzal, irritable bowel syndrome product Buscopan, painkiller ...

Metabolex has entered into an agreement with Sanofi–Aventis for the development of small molecules that target G protein-coupled receptor 119 (GPR119), the most advanced of which is in a Phase ...

Sanofi and Boehringer Ingelheim (BI), drug giants ... with Ahmedabad-based Zydus Cadila for two gastrointestinal brands Buscopan and Dulcolax, re-launching those as Buscogast and Dulcoflex.